Dr. Ticiana A. Leal
Claim this profileUniversity of Wisconsin Hospital and Clinics
Expert in Non-Small Cell Lung Cancer
Expert in Lung Cancer
16 reported clinical trials
23 drugs studied
Area of expertise
1Non-Small Cell Lung Cancer
Global LeaderStage III
Stage IV
Stage II
2Lung Cancer
Global LeaderStage III
Stage IV
Stage II
Affiliated Hospitals
Clinical Trials Ticiana A. Leal is currently running
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Genetic Testing
for Early-Stage Lung Cancer
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Recruiting0 awards N/A4 criteria
More about Ticiana A. Leal
Clinical Trial Related4 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Ticiana A. Leal has experience with
- Carboplatin
- Talazoparib
- Bevacizumab
- Cisplatin
- Atezolizumab
- Pembrolizumab
Breakdown of trials Ticiana A. Leal has run
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
- Durvalumab + Chemoradiation for Non-Small Cell Lung Cancer
- Osimertinib + Bevacizumab for Lung Cancer
- Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread
Lung Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ticiana A. Leal specialize in?
Ticiana A. Leal focuses on Non-Small Cell Lung Cancer and Lung Cancer. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage III patients, or patients who are Stage IV.
Is Ticiana A. Leal currently recruiting for clinical trials?
Yes, Ticiana A. Leal is currently recruiting for 9 clinical trials in Madison Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Ticiana A. Leal has studied deeply?
Yes, Ticiana A. Leal has studied treatments such as Carboplatin, Talazoparib, Bevacizumab.
What is the best way to schedule an appointment with Ticiana A. Leal?
Apply for one of the trials that Ticiana A. Leal is conducting.
What is the office address of Ticiana A. Leal?
The office of Ticiana A. Leal is located at: University of Wisconsin Hospital and Clinics, Madison, Wisconsin 53792 United States. This is the address for their practice at the University of Wisconsin Hospital and Clinics.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.